Varsak Nalan, Topaloğlu Mert, Özdemir Elif
Department of Psychiatry, Malazgirt State Hospital, Muş, Turkey.
Department of Emergency, Malazgirt State Hospital, Muş, Turkey.
Clin Psychopharmacol Neurosci. 2021 Nov 30;19(4):786-788. doi: 10.9758/cpn.2021.19.4.786.
On March 11, 2020, the World Health Organization declared that the infection of novel coronavirus identified in Wuhan, China, is a pandemic. Various studies have shown that SARS-CoV-2 infection can trigger psychiatric effects such as anxiety, depression, and bipolar disorder. Here, we reported a case with no significant psychiatric history who experienced first-episode mania during the COVID-19 treatment. On the third day of hospitalization, the patient's mood was elevated, she thought she can treat other patients with her special power, she was talkative and irritable. Olanzapine 20 mg was started and the patient's score on the Young Mania Rating Scale decreased on the 17th day. Psychiatric outcomes associated with covid 19 are just emerging and it seems likely to be a potential engagement for psychiatric professionals in the future. More studies are required in terms of the treatment, course, and follow-up of psychiatric sequelae in these patients.
2020年3月11日，世界卫生组织宣布，在中国武汉发现的新型冠状病毒感染已成为全球大流行疾病。多项研究表明，严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染可引发焦虑、抑郁和双相情感障碍等精神方面的影响。在此，我们报告了1例既往无明显精神病史的患者，其在2019冠状病毒病（COVID-19）治疗期间出现首次发作的躁狂症状。住院第3天，患者情绪高涨，认为自己能用特殊能力治疗其他患者，言语增多且易激惹。开始使用20毫克奥氮平治疗，第17天时患者的杨氏躁狂评定量表评分降低。与COVID-19相关的精神科转归情况才刚刚出现，未来很可能会成为精神科专业人员需要关注的一个领域。对于这些患者精神科后遗症的治疗、病程及随访，还需要开展更多研究。
